Pro Medicus provided earnings guidance for the second half of 2014. For the period, the company maintains its previous guidance that the second half is expected to be stronger than the reported first half results, as revenue from the VISN 23 contract commences and there is the full impact of six months of vRad revenue.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
132.1 AUD | +1.57% | +7.85% | +37.90% |
10/06 | Three companies to bet on medical AI | |
28/05 | Pro Medicus' US Subsidiary Signs Five New Contracts Worth at Least AU$45 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.90% | 882.04Cr | |
-1.88% | 3.04TCr | |
+42.57% | 458.79Cr | |
-29.79% | 263.98Cr | |
-9.44% | 158.67Cr | |
-22.85% | 134.97Cr | |
-37.12% | 107.61Cr | |
+10.08% | 92Cr | |
-42.90% | 80Cr | |
-21.59% | 68Cr |
- Stock Market
- Equities
- PME Stock
- News Pro Medicus Limited
- Pro Medicus Provides Earnings Guidance for the Second Half of 2014